MDL-001
SARS-CoV-2 and Variants
Key Facts
About Model Medicines
Model Medicines is a private, preclinical-stage biotech leveraging artificial intelligence to accelerate drug discovery. Its core technology, the GALILEO™ platform, is used to identify and validate novel compounds, with a lead program (MDL-001) targeting multiple viruses via a common RdRp mechanism. The company emphasizes validation through partnerships with top academic labs and is advancing a pipeline of fully-owned assets toward IND-enabling studies.
View full company profileAbout Model Medicines
Model Medicines is a private, preclinical-stage biotech leveraging artificial intelligence to accelerate drug discovery. Its core technology, the GALILEO™ platform, is used to identify and validate novel compounds, with a lead program (MDL-001) targeting multiple viruses via a common RdRp mechanism. The company emphasizes validation through partnerships with top academic labs and is advancing a pipeline of fully-owned assets toward IND-enabling studies.
View full company profileAbout Model Medicines
Model Medicines is a private, preclinical-stage biotech leveraging artificial intelligence to accelerate drug discovery. Its core technology, the GALILEO™ platform, is used to identify and validate novel compounds, with a lead program (MDL-001) targeting multiple viruses via a common RdRp mechanism. The company emphasizes validation through partnerships with top academic labs and is advancing a pipeline of fully-owned assets toward IND-enabling studies.
View full company profileAbout Model Medicines
Model Medicines is a private, preclinical-stage biotech leveraging artificial intelligence to accelerate drug discovery. Its core technology, the GALILEO™ platform, is used to identify and validate novel compounds, with a lead program (MDL-001) targeting multiple viruses via a common RdRp mechanism. The company emphasizes validation through partnerships with top academic labs and is advancing a pipeline of fully-owned assets toward IND-enabling studies.
View full company profileAbout Model Medicines
Model Medicines is a private, preclinical-stage biotech leveraging artificial intelligence to accelerate drug discovery. Its core technology, the GALILEO™ platform, is used to identify and validate novel compounds, with a lead program (MDL-001) targeting multiple viruses via a common RdRp mechanism. The company emphasizes validation through partnerships with top academic labs and is advancing a pipeline of fully-owned assets toward IND-enabling studies.
View full company profile